NAD+ falls about 50% between ages 20 and 60; you can't supplement NAD+ directly, so oral precursors (NMN, NR, niacinamide, niacin) are used — but only human trials, not mouse studies, should guide the choice.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in more than 500 enzymatic reactions in the human body, making it one of the most abundant and fundamental molecules in cellular metabolism. It shuttles electrons in the mitochondrial electron transport chain (NAD+/NADH cycling), serves as a substrate for sirtuins (SIRT1-7, the "longevity proteins"), and fuels PARPs (poly-ADP ribose polymerases, the DNA repair enzymes). It is also one of the most commercially hyped molecules in the longevity supplement space, with global NAD+ supplement sales exceeding $1 billion annually.
The scientific case for NAD+ supplementation is genuine — NAD+ levels decline measurably with age, and that decline has real consequences for energy metabolism, DNA repair, and cellular resilience. The commercial reality is more complicated: the gap between mouse study results and human clinical trial results is significant; the optimal form and dose of NAD+ precursor supplementation in humans remains contested; and the marketing claims substantially outpace the clinical evidence. This guide focuses exclusively on human data.
Understanding the biochemistry helps evaluate which supplement form to choose. NAD+ cannot be taken orally with significant bioavailability — it does not cross cell membranes intact and is rapidly degraded in the GI tract. Oral NAD+ supplements require conversion to a precursor form before absorption.
| Form | Pathway to NAD+ | Key Human Evidence | Key Consideration |
|---|---|---|---|
| NMN (nicotinamide mononucleotide) | NMN → NAD+ (direct, via NMN-AT enzyme); also can convert to NR then to NAD+ | Yoshino 2021 (Science, N=25): muscle NAD+ increase confirmed; 2023 meta-analysis: 5 RCTs positive; most NMN human trials smaller N than NR trials | Best animal data-to-human data translation; slight advantage in muscle tissue NAD+ delivery vs NR in some studies; more expensive than NR; sublingual form bypasses gut (potential bioavailability advantage, less studied) |
| NR (nicotinamide riboside) | NR → NMN → NAD+; also → Nam (nicotinamide) → recycles back | Brenner 2019 (Cell Reports, N=120): 60% blood NAD+ increase; multiple Phase 1/2 trials in cardiac, neurological, and metabolic conditions (mostly safety/pharmacokinetic outcomes); most human-studied NAD+ precursor | Most human clinical trial data of any NAD+ precursor; blood NAD+ increases well-documented; tissue-level NR studies less robust than NMN; Brenner (co-inventor of NR patent) conflict of interest acknowledged but does not invalidate data |
| Niacinamide (nicotinamide) | Nam → NMN → NAD+ (salvage pathway; rate-limited by NAMPT) | Long history of use; FDA-approved; multiple studies showing NAD+ precursor activity | Cheapest option; sirtuin inhibition concern at >500mg/day (theoretical, clinical significance unclear); NAMPT rate-limiting step may mean niacinamide supplementation less efficient at raising tissue NAD+ than NMN/NR when NAMPT is depleted (common in aging) |
| Niacin (nicotinic acid) | Different pathway (Preiss-Handler); more efficient at raising NAD+ in liver and fat tissue | Well-studied; FDA-approved for dyslipidemia at pharmacological doses | Niacin flush (vasodilation, flushing, itching) at doses >50mg; effectively raises NAD+ but less targeted to pathways most relevant to sirtuin activation; not typically recommended as a longevity supplement at high doses due to flush and potential liver effects at gram doses |
| NAD+ (oral) | Degraded in GI tract → absorbed as precursor fragments; not bioavailable intact | No human evidence of advantage over precursors; some NAD+ products market "oral NAD+" — these are inefficient | Do not buy oral NAD+; buy a precursor (NMN, NR, or niacinamide) |
The most important principle: most NAD+ biology research is in mouse models. Mice convert supplements to tissue NAD+ more efficiently than humans, respond to treatment faster, and live shorter lives (meaning NAD+ effects on longevity endpoints are more measurable). Human translation is incomplete. The following is what human RCTs have and have not shown.
NMN and NR raise blood NAD+ levels in humans. This is well-replicated across multiple RCTs. Blood NAD+ reliably increases with NMN or NR supplementation at 250–1000mg/day doses.
NMN raises skeletal muscle NAD+ metabolites. Yoshino 2021 — using muscle biopsies — confirmed that 250mg NMN for 10 weeks increased intramuscular NAD+ metabolomes. This is tissue-level confirmation, not just a blood proxy.
NMN improves muscle insulin sensitivity and physical performance in older women. Yoshino 2021 secondary findings: improved skeletal muscle insulin signaling; a 2022 Japanese RCT (N=108): 250mg NMN for 12 weeks improved walking speed and grip strength in older adults.
NR is safe at doses up to 2000mg/day. Multiple Phase 1 trials confirm safety profile. No serious adverse events at studied doses.
Yoshino 2021 found no improvement in insulin sensitivity in the overall population (only in the subgroup with low muscle insulin sensitivity at baseline). This was contrary to dramatic mouse data. Metabolic benefits in humans are smaller and more conditional than mouse data suggested.
No human RCT has shown NAD+ precursor supplementation increases lifespan, reduces biological age (epigenetic clock), or meaningfully reduces cardiovascular disease risk as a primary endpoint. These effects are inferred from mechanistic data (sirtuins, PARP, mitochondrial function) and mouse studies.
The optimal dose and form for specific outcomes remains unknown. Higher doses (>600mg NMN or NR) don't consistently produce proportionally greater benefits. Tissue distribution differs between forms but clinical significance is unclear.
NR and NMN have not been compared head-to-head in a large, powered human RCT. Form choice is based on mechanistic reasoning, cost, and extrapolation from animal data — not direct comparative human trials.
For NAD+ precursor supplementation in adults over 40:
• NMN 250–500mg/day (morning, with or without food; sublingual if available for potentially better bioavailability though this comparison is not confirmed in humans) — best muscle tissue evidence from Yoshino 2021
• OR NR 500mg/day — most human trial experience, well-studied safety profile, widely available
• OR niacinamide 250–500mg/day — lowest cost option; avoid >500mg/day if concerned about sirtuin inhibition (theoretical risk); most conservative choice with least direct evidence
• Resveratrol and quercetin are often co-marketed as "sirtuin activators" to pair with NMN — Sinclair's protocol includes resveratrol; human evidence for resveratrol's sirtuin activation is weak
• Lifestyle factors that raise NAD+: fasting (increases NAMPT expression), exercise (increases NAMPT and mitochondrial NAD+ demand), caloric restriction — these have more robust human evidence for NAD+-pathway effects than any supplement
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.